rs1165196 — SLC17A1 SLC17A1 T269I (NPT1)

SLC17A1 T269I — The NPT1 Urate Exporter Gain-of-Function Variant

The kidneys are the primary route of uric acid excretion, and their efficiency depends on a balance between transporters that reabsorb urate from the filtrate and those that secrete it into urine for elimination. On the apical (urine-facing) surface of the proximal tubule, NPT1 (sodium-dependent phosphate transport protein 1), encoded by SLC17A1, acts as a urate efflux transporter — pumping uric acid from tubular cells into the tubular lumen¹¹ NPT1 (sodium-dependent phosphate transport protein 1), encoded by SLC17A1, acts as a urate efflux transporter — pumping uric acid from tubular cells into the tubular lumen. rs1165196 is a missense variant in SLC17A1 that directly changes the protein's amino acid at position 269 (Thr↔Ile), and this change has measurable consequences for how efficiently NPT1 exports urate from the kidney.

The Mechanism

The A allele at rs1165196 encodes isoleucine at position 269 (Ile269) — the common form of NPT1 in most global populations. The G allele encodes threonine at the same position (Thr269), and this substitution alters the transport kinetics of the protein. Functional studies using Xenopus oocyte expression systems showed that the Thr269 variant increases urate transport by raising the maximum transport rate (Vmax) without changing the substrate affinity (Km) or membrane expression level²² the Thr269 variant increases urate transport by raising the maximum transport rate (Vmax) without changing the substrate affinity (Km) or membrane expression level
Sakiyama et al. 2016: gain-of-function mechanism confirmed in NPT1 I269T (Thr269) variant. This means the Thr269 protein is intrinsically more active — each transporter molecule moves more urate per unit time — without the cell needing to produce more copies.

The net effect is a higher urate secretory rate in the proximal tubule, directly lowering the serum urate setpoint in Thr269 carriers. Carriers of the Ile269 form (A allele) have baseline NPT1 activity and correspondingly higher serum urate relative to Thr269 carriers.

The Evidence

The functional significance of rs1165196 was established in a study of 582 Japanese gout patients and controls: the Thr269 variant significantly decreased risk of renal underexcretion gout (OR 0.73, p=0.031), confirming that enhanced NPT1 urate export reduces the most common gout subtype³³ the Thr269 variant significantly decreased risk of renal underexcretion gout (OR 0.73, p=0.031), confirming that enhanced NPT1 urate export reduces the most common gout subtype
Chiba et al. 2015, Arthritis & Rheumatology. Renal underexcretion gout accounts for approximately 80–90% of primary gout cases, making NPT1 function a clinically important determinant. An earlier study of 103 Japanese male gout patients found the coding-equivalent C allele (Thr269) protective against gout at OR 0.55 (p=0.0035)⁴⁴ the coding-equivalent C allele (Thr269) protective against gout at OR 0.55 (p=0.0035)
Urano et al. 2010, Annals of the Rheumatic Diseases, with a significant gene-obesity interaction: the protective effect on serum uric acid was amplified in individuals with BMI ≥25.

The rs1165196 locus overlaps with the broader SLC17A1 GWAS signal for serum urate. The linked intronic variant rs1183201 reached genome-wide significance (p=3.0×10⁻¹⁴) in a meta-analysis of 28,141 Europeans, confirming that this chromosomal region materially influences the renal urate setpoint across populations.

The Thr269 allele (G on the plus strand) reaches its highest frequency in Europeans (~44%) and South Asians (~47%), while the Ile269 allele (A) is dominant in East Asian (~85%) and African (~89%) populations. This ancestry stratification helps explain why gout prevalence differs substantially across populations and is particularly relevant for interpreting genetic risk in multi-ancestry settings.

Practical Actions

For carriers of the AA genotype (Ile/Ile), NPT1 operates at baseline efficiency. Since approximately 80–90% of gout is driven by renal underexcretion rather than overproduction, reduced secretory capacity from this locus compounds with other urate transport variants to elevate the serum urate setpoint. Dietary purine management (limiting shellfish, organ meats, and fructose-sweetened beverages) reduces the substrate load the kidney must clear.

For AG heterozygotes, one NPT1 allele carries the gain-of-function Thr269 and the other the baseline Ile269, yielding intermediate urate secretory capacity. Periodic monitoring of serum uric acid is warranted, especially if other urate-raising variants are present.

Interactions

rs1165196 is in linkage disequilibrium (r² ≈ 0.8–0.9) with the intronic variant rs1183201 in the same gene, which has more direct GWAS association data for serum urate. Both variants capture the same biological signal — NPT1-mediated urate secretory capacity at the SLC17A1 locus. When both are genotyped, rs1165196 provides the mechanistic interpretation (gain-of-function protein change) while rs1183201 provides population-level effect size data.

The most clinically important interaction is with rs2231142 in ABCG2, the second major apical urate secretory transporter. ABCG2 Q141K (rs2231142 T allele) reduces ABCG2 transport activity by approximately 50%, and carriers of both SLC17A1 Ile269 (A allele) and ABCG2 Q141K have dual impairment of apical urate secretion — both major secretory routes compressed simultaneously. This compound effect is especially prevalent in East Asian populations and substantially elevates gout risk beyond either variant alone.